AGM/EGMJun 4, 2026, 04:28 PM
BioMarin Stockholders Approve 7.65M Share Increase for Equity Plan
AI Summary
BioMarin Pharmaceutical Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 7,650,000. Additionally, stockholders elected ten directors to the Board, ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026, and approved the compensation of named executive officers on an advisory basis. All proposals presented at the meeting received stockholder approval.
Key Highlights
- BioMarin stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing reserved shares by 7,650,000.
- Ten directors were elected to the Board, including Elizabeth M. Anderson (152,826,855 For) and Barbara W. Bodem (162,832,241 For).
- KPMG LLP was ratified as the independent registered public accounting firm for 2026 with 170,867,335 votes For.
- The advisory vote on the compensation of named executive officers was approved with 142,742,800 votes For.
- A total of 193,270,028 shares were entitled to vote at the Annual Meeting, with 175,813,292 shares present.
Price Impact
More from BMRN